ReviewInternational journal of bioprinting2017
Digital biomanufacturing supporting vascularization in 3D bioprinting.
Review in International journal of bioprinting, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training.Stem cells translational medicine · 2020Article
- Biofabrication offers future hope for tackling various obstacles and challenges in tissue engineering and regenerative medicine: A Perspective.International journal of bioprinting · 2019Article
- Cell powered biobots and more perspectives for IJB.International journal of bioprinting · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synergies in bioprinting are appearing from individual researchers focusing on divergent aspects of the technology. Many are now evolving from simple mono-dimensional operations to model-controlled multi-material, interpenetrating networks using multi-modal deposition techniques. Bioinks are being designed to address numerous critical process parameters. Both the cellular constructs and architectural design for the necessary vascular component in digitally biomanufactured tissue constructs are being addressed. Advances are occurring from the topology of the circuits to the source of the of the biological microvessel components. Instruments monitoring and control of these activates are becoming interconnected. More and higher quality data are being collected and analysis is becoming richer. Information management and model generation is now describing a "process network." This is promising; more efficient use of both locally and imported raw data supporting accelerated strategic as well as tactical decision making. This allows real time optimization of the immediate bioprinting bioprocess based on such high value criteria as instantaneous progress assessment and comparison to previous activities. Finally, operations up- and down-stream of the deposition are being included in a supervisory enterprise control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.